SUMMARY Fifty six adult patients were randomised to treatment with flecainide (group 1, n = 29) or a combination of digoxin and disopyramide (group 2, n = 27) for acute atrial fibrillation and flutter after cardiac surgery. Intravenous flecainide was given as a 2 mg/kg bolus over 20 minutes followed by an infusion (0-2 mg/kg per hour) for 12 hours. Group 2 were given digoxin (0-75 mg) intravenously followed two hours later by an intravenous bolus of disopyramide (2 mg/kg) and an infusion (0 4 mg/kg per hour) for 10 hours. Within 12 hours sinus rhythm was restored in 86% of the group 1 (25 patients) and 89% of the group 2 (24 patients). The median time to reversion was significantly shorter in group 1 (80 minutes, range 30-180 minutes) than group 2 (220 minutes, range 138-523 minutes). None of the patients in group 1 and four of the patients in group 2 had transient relapses into atrial fibrillation during the 12 hours of intravenous treatment. There were five late relapses in group 1 and seven in group 2 during subsequent oral treatment. Two group 1 patients and two group 2 patients showed adverse drug effects. Intractable ventricular arrhythmias occurred after five days of oral treatment in one patient (group 1) who had poor left ventricular function, hepatic impairment, and toxic concentrations of drugs at the time of death.
The early postoperative course after open heart surgery is complicated by supraventricular arrhythmias (usually atrial fibrillation or flutter) in 15- 90%/ of patients.'`3 Although reversion to sinus rhythm may occur promptly without treatment, an appreciable proportion of patients will have persistent arrhythmias associated with a rapid ventricular rate, causing distress, impaired myocardial performance, and symptomatic haemodynamic deterioration.
An earlier study at our hospital showed that intravenous sotalol was as effective as a combination of digoxin and disopyramide in restoring sinus rhythm and that it acted significantly faster. 
Results
Of the 58 eligible patients, 30 were randomly assigned to group 1 and 28 to group 2. In one of the group 2 patients with atrial flutter 1:1 atrioventricular conduction developed before the start of antiarrhythmic treatment. The patient's rhythm rapidly degenerated into ventricular fibrillation necessitating urgent cardioversion with the re-establishment of sinus rhythm. This patient was excluded from the analysis.
Another patient from group 1 was treated with intravenous verapamil 30 minutes before the flecainide bolus and reverted to sinus rhythm after 3X5 hours. This patient was also excluded from the analysis because another antiarrhythmic was used within 48 hours of the study.
The bolus; in 11 patients the rhythm reverted within an hour. Plasma concentrations of flecainide ranged from 160 to 450 ng/ml (mean 306 ng/ml) at one hour and from 280 to 657 ng/ml (mean 434 ng/ml) at 12 hours. In four patients sinus rhythm did not return during the 12 hours of intravenous flecainide treatment. In two ofthese, both with atrial fibrillation and flutter, atrial flutter persisted after full intravenous dose of flecainide had been given. One reverted to sinus rhythm six hours after starting oral flecainide and the other returned to sinus rhythm after 82 hours on digoxin and disopyramide after oral flecainide had been stopped. A third patient remained in atrial fibrillation despite the full flecainide infusion, and this arrhythmia persisted for the next five days despite treatment with oral digoxin, flecainide, and, later, quinidine. On day 5 electrical cardioversion to sinus rhythm was successful. The fourth patient received the full dose of intravenous flecainide and remained in atrial fibrillation despite continued oral flecainide (initially at 200 mg/day and later 300 mg/ day). In group 2, 24 out of 27 patients reverted to sinus rhythm within 12 hours (figure). The time to reversion after the bolus ofdigoxin ranged from 138 to 523 minutes (median 220 minutes). The time to reversion was significantly longer than that in group 1 (p < 0l001). Five patients reverted with digoxin alone at a median of 105 minutes after the bolus and 19 required the combination of digoxin and disopyramide (reverting at a median of315 minutes after the start oftreatment). The three patients in group 2 with persistent arrhythmias at 12 hours returned to sinus rhythm after 24, 29, and 29 hours respectively of continued oral digoxin and disopyramide.
No patients in group 1 relapsed during the 12 hours of intravenous flecainide; however, five patients relapsed 5-91 hours after the flecainide infusion. In two of these the initial oral flecainide dose had been delayed by nine hours. All five patients reverted to stable sinus rhythm 3-59 hours after relapse, two were continuing to take flecainide 200 mg/day, one flecainide and digoxin, one flecainide 300 mg/day, and one on digoxin and quinidine.
Two patients who reverted with digoxin alone relapsed 10 minutes and 30 minutes later. They were given intravenous disopyramide and in both of them sinus rhythm retumed within 60 minutes. Two patients who responded initially to digoxin and disopyramide relapsed during the disopyramide infusion at two hours and 10 hours. On continued intravenous disopyramide they reverted to sinus rhythm at 10 minutes and five hours respectively. Seven patients who reverted during treatment with digoxin and disopyramide relapsed (after the disopyramide infusion) 6-114 hours after the initial reversion. Three continued on digoxin and disopyramide and reverted to sinus rhythm 10 hours, 13 hours, and 70 hours later. Three were treated with digoxin and quinidine and reverted at two, 15, and 19 hours; and another reverted at 12 hours with digoxin, quinidine, and atrial overdrive pacing for persistent atrial flutter. SIDE 
EFFECTS
Most patients did not show any untoward changes in vital signs after operation. In one patient blood pressure fell significantly from 120 mm Hg to 90 mm Hg (systolic) immediately after intravenous flecainide. In this case the rhythm was atrial fibrillation with a ventricular rate of 160/min. After the administration of 100 ml of colloid (Haemacel) the blood pressure returned promptly to its previous value without further sequelae.
Another patient, a 68 year old man with congestive heart failure, underwent repeat operation for a leaking mitral valve prosthesis and single coronary artery graft, and atrial fibrillation developed postoperatively. The preoperative left ventricular ejection fraction was 0-34. Serum concentrations of hepatic transaminases were raised before operation. The arrhythmia persisted despite treatment with flecainide and the dose was increased to 300 mg/day.
The QRS complex progressively widened to 0 17 seconds over the next three days without reversion to sinus rhythm. Then treatment with digoxin (0-25 mg/day) then started. Within 36 hours the patient became dyspnoeic and developed sustained ventricular tachycardia (QRS width 0-24 seconds), which was refractory to repeated cardioversion and several antiarrhythmic agents. Cardiopulmonary resuscitation was unsuccessful and at death the 500 Gavaghan, Keogh, Kelly, Campbell, Thorburn, Morgan plasma concentration of flecainide was 2000 ng/ml (4 0 kmol/1).
No adverse effects were noted during the initial 12 hours of treatment in group 2, however, in two patients oral disopyramide (600 mg/day) was stopped because of acute urinary retention.
Discussion
Several recent studies have shown that flecainide acetate is an effective treatment for converting atrial fibrillation and atrioventricular reentrant tachycardias to sinus rhythm. ' We found that flecainide was as effective as a combination of digoxin and disopyramide in reverting acute onset arrhythmia within 12 hours of start of treatment (86% v 89% respectively). The time to reversion to sinus rhythm was significantly shorter in the flecainide group, with 72% of patients reverting within two hours of treatment compared with only 21% of patients receiving the standard treatment.
The median time to reversion on flecainide was almost one third that of the combination of digoxin and disopyramide (80 min v 220 min, p < 0 001). Furthermore, during the observation period of intravenous and continued oral treatment there were far fewer relapses in the flecainide group.
The choice of flecainide as first line treatment for symptomatic atrial arrhythmias after open heart surgery follows from previous studies at our hospital of the efficacy of disopyramide and sotalol in similar patients.'4 Unfortunately side effects often limited the continued use of disopyramide and sotalol and prompted this trial of an alternative treatment. Several studies have evaluated the prophylactic use of low dose f blockers in the immediate postoperative period and have shown a significant reduction in the incidence of supraventricular arrhythmias.23 4 The frequency of arrhythmia in the control groups in these studies (16-94%) has, in most cases, been higher than the 25% previously found at our hospital.
There is an understandable reluctance to treat all patients in order to prevent an arrhythmia in a limited number most ofwhom will respond promptly to specific antiarrhythmic treatment. As a result of the rapid restoration of sinus rhythm with this flecainide treatment, it has now been adopted at our hospital as the usual treatment for postoperative atrial arrhythmias.
Side effects were equally common in both groups, however, a lethal arrhythmia developed while one patient was being treated with flecainide (300 mg/ day). The risk in this patient was increased by poor left ventricular function and repeat operation for mitral valve and coronary artery disease. In such cases the incidence of arrhythmogenic effects of antiarrhythmic agents approaches 20% and may be associated with toxic plasma concentrations.5 Frequent monitoring of plasma concentrations with cautious increases in dose (not more often than every four days) is important in patients with heart failure, who have a prolonged elimination half life.617
